Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Iowa for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Iowa only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Iowa (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Kyle Alliman (NPI 1437360351)

Field	Value
Entity Type	Individual
Organization	Kyle Alliman
Address	6200 Westown Pkwy
City	West Des Moines
State	IA
ZIP	50266
Taxonomy	Ophthalmology Physician
NPI Enumerated	May 24, 2007

Payer Source	Total Paid
Medicare	$8.7M
Medicaid	$0

Key Findings

This provider is effectively single-payer on record: lifetime Medicare revenue is $8.7M and there is no Medicaid billing on file, so all uncovered claims activity in the dataset is Medicare-derived. That concentration means the practice’s revenue and utilization profile should be evaluated primarily through the lens of Medicare reimbursement and drug-pricing dynamics.

Revenue is highly concentrated in three injectable ophthalmology drugs: J2777, J0178, and J2778 together account for 89.9% of the provider’s Medicare revenue, with individual shares of 57.9%, 20.4%, and 11.6% respectively. This concentration indicates the provider’s financial performance is driven overwhelmingly by high-volume intravitreal biologic administration rather than by general office visits or minor procedures.

The mix of top codes and code descriptions shows a retina-focused, injection-centric operation: J2777 (faricimab), J0178 (aflibercept), and J2778 (ranibizumab) dominate revenue while high volumes of 67028 (injection into the vitreous chamber) and 92134 (computerized retinal imaging) demonstrate routine, procedure-driven management of retinal disease. The presence of 92134 (5.5K claims, $153.1K revenue) alongside thousands of injection claims is consistent with a practice that pairs frequent imaging with biologic therapy.

For several high-revenue items the provider is a national outlier: J2777 ranks #4 of 2039 providers nationally (100th percentile; extreme outlier), 67028 ranks #14 of 4255 providers (100th percentile; extreme outlier), 92134 ranks #24 of 26868 providers (100th percentile; extreme outlier), and 99213 likewise appears as an extreme outlier by percentile. These rankings signal a dominant national footprint for administration of faricimab and high throughput for injection visits and retinal imaging compared with peers.

Not all leading drug codes show the same competitive intensity: J2778 ranks #33 of 1208 providers (97th percentile; notably above typical national volume) indicating a substantially above-average presence for ranibizumab, while J0178 ranks #289 of 3204 providers (91th percentile; typical, unremarkable volume) suggesting more typical national participation for aflibercept. This uneven ranking across biologics hints at programmatic preference or local formulary/contracting effects that favor faricimab at this location.

Although most revenue is tied to injections and imaging, the provider also bills surgical retina codes (for example 67042 with 47 claims and $38.5K revenue and 67028 with 4.5K claims and $391.8K revenue), indicating capacity to deliver both office-based intravitreal therapy and some operative retinal procedures. These surgical and procedure codes represent a minority of Medicare revenue but demonstrate clinical breadth beyond routine injections.

Dependence on high-dollar drug administration creates payer and reimbursement sensitivity: with no Medicaid billing on file and nearly all revenue coming from Medicare, the practice’s topline is exposed to changes in Medicare drug payment policy, coverage decisions, or utilization management for intravitreal biologics like those billed under J2777/J0178/J2778. Absence of a Medicaid revenue stream means there is no immediate state-program revenue diversification recorded here.

The provider’s NPI was enumerated on 2007-05-24 (~19 years ago), indicating an established billing history to Medicare; that tenure combined with sustained, high-volume billing for injections and retinal imaging supports the interpretation of a mature, retina-focused practice rather than a newer or low-volume office.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

22 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J2777	Injection, faricimab‑svoa, 0.1 mg	174,000	$30	$5M
J0178	Injection, aflibercept, 1 mg	2,580	$690	$1.8M
J2778	Injection, ranibizumab, 0.1 mg	5,670	$180	$1M
67028	The provider injects a medication into the vitreous chamber of the eye as an isolated procedure or a separate procedure unrelated to any other procedure being performed on the eye.	4,500	$90	$391.8K
92134	The provider performs computerized diagnostic imaging of the retina in the posterior segment (back part) of the eye, interprets the data, and provides a report. The service may be on one or both eyes.	5,470	$30	$153.1K
99213	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a low level of medical decision making, and/or the…	1,510	$60	$87.3K
J3590	Unclassified biologics	330	$150	$48.6K
J7312	Injection, dexamethasone, intravitreal implant, 0.1 mg	290	$160	$45.3K
67042	In this procedure, the provider removes vitreous humor, the gelatinous material that gives shape to the eye, using a mechanical cutting tool. He removes the internal limiting membrane of the retina…	50	$820	$38.5K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	430	$80	$36K

Showing 1–10 of 22

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 22 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Iowa Distribution

Kyle Alliman — 6 of 22 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Iowa

Full comparison — all codes billed, vs. state median

22 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J2777	1	20	43,140	$30	$1.7M
J0178	5	40	640	$690	$760.2K
J2778	1	20	780	$180	$259.9K
67028	1	60	420	$80	$80.6K
J7312	1	10	200	$160	$32.9K
67042	4	20	20	$900	$28.8K
J3590	7	30	140	$100	$26.7K
92014	117	500	200	$70	$19.8K
67036	6	10	20	$740	$15.5K
67108	16	20	20	$830	$15K

Showing 1–10 of 22

Related Providers

Other providers that share a Tax Identification Number (TIN) with Kyle Alliman, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Wolfe Clinic Inc	IA	Ophthalmology Physician	$0	$18.2M
Thomas Buroker	IA	Medical Oncology Physician	$9.4M	$0
Alex Kartvelishvili	IA	Ophthalmology Physician	$8.1M	$0
Paul Boeke	IA	Ophthalmology Physician	$7.1M	$0
Austin Strohbehn	IA	Retina Specialist (Ophthalmology) Physician	$5.8M	$0
Jeremy Deutsch	KS	Hematology & Oncology Physician	$5.7M	$0
Robert Behrens	IA	Medical Oncology Physician	$5.2M	$0
Matthew Mcknight	IA	Foot & Ankle Surgery Podiatrist	$4.7M	$23.5K
James Singer	IA	Retina Specialist (Ophthalmology) Physician	$4.1M	$0
Christopher Haupert	IA	Retina Specialist (Ophthalmology) Physician	$3.9M	$0

Nearby Providers

Other providers in the same ZIP code as Kyle Alliman, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Iowa Physicians Clinic Medical Foundation	IA	General Practice Physician	$0	$102.7M
Link Associates	IA	Intellectual and/or Developmental Disabilities Community Based Residential Treatment Facility	$0	$83.3M
Iowa Family Services, Inc	IA	Community/Behavioral Health Agency	$0	$9.9M
Revell-warrington Dental PC	IA	Pediatric Dentistry	$0	$9.2M
Csa	IA	Community/Behavioral Health Agency	$0	$8.8M
City Of West Des Moines	IA	Land Ambulance	$726.2K	$5.1M
Wolfe Surgery Center, LLC	IA	Ambulatory Surgical Clinic/Center	$4.1M	$1.3M
Iowa Home Care, LLC	IA	Home Health Agency	$0	$5.4M
The Iowa Clinic PC	IA	Family Medicine Physician	$0	$5.4M
Divine Touch Of Iowa LLC	IA	Intellectual and/or Developmental Disabilities Community Based Residential Treatment Facility	$0	$4.8M

Kyle Alliman — Billing Profile & Reimbursement Data

Sign up for Kyle Alliman — Billing Profile & Reimbursement Data policy alerts

Kyle Alliman — Billing Profile & Reimbursement Data

Sign up for Kyle Alliman — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References